Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9311985 | 0.88 | KMT2A (0.75) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL1272337 | 0.84 | KMT2A (0.70) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL2169180 | 0.82 | MEN1 (0.68) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL29389982 | 0.82 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL27641814 | 0.82 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL17434797 | 0.82 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL7825585 | 0.82 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL8286793 | 0.82 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL5456482 | 0.82 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL31146466 | 0.82 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | KMT2A 1262/4885MEN1 824/4885NPC1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.